Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAPIDO study in high-risk rectal cancer
NL-OMON47895Phase 3Active, not recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Mar 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of capecitabine and oxaliplatin in rectal adenocarcinoma (2 arms), sponsored by University Medical Center Groningen. Primary endpoint: Disease-related treatment failure. Started Mar 2012; status: active, not recruiting.
02
Drugs
capecitabineoxaliplatin
03
Conditions
rectal adenocarcinoma
Beyond the preview
Go deeper on NL-OMON47895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47895.